menu
    • menu
    [{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Completes Dosing of First Cohort in Phase 1\/2 Clinical Trial of NEXI-001 in Relapsed Acute Myelogenous Leukemia (AML)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune First Patient Dosed in NexImmune Phase 1\/2 Clinical Trial of NEXI-002 in Multiple Myeloma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-002","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune to Highlight Preliminary Results from Phase 1\/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"NEXI-001","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"The Laura and Isaac Perlmutter Cancer Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Melanoma Research Collaboration with NYU Langone\u2019s Perlmutter Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","year":"2022","type":"Collaboration","leadProduct":"Neoantigen-specific CD8+ T Cells","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NexImmune \/ The Laura and Isaac Perlmutter Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"Columbia University Irving Medical Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center\u2019s Herbert Irving Comprehensive Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Collaboration","leadProduct":"Adoptive Cell Therapy","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NexImmune \/ Columbia University Irving Medical Center","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"$0.6 million","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Partnership","leadProduct":"T1D Antigen-specific Nanoparticle","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"NEXI-003","moa":"CD3\/CD4","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"KBI Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Agreement","leadProduct":"HLA IgG4 Fusion Proteins","moa":"T cell","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NexImmune \/ NexImmune","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"National Institute of Neurological Disorders and Stroke","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Collaboration","leadProduct":"T-Cell Therapy","moa":"","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NexImmune \/ National Institute of Neurological Disorders and Stroke","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company\u2019s AIM Platform to Treat Viral Diseases","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"NEXI-004","moa":"","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"NexImmune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"NexImmune .."},{"orgOrder":0,"company":"NexImmune","sponsor":"JDRF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery","graph3":"NexImmune","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"NexImmune \/ JDRF","highestDevelopmentStatusID":"2","companyTruncated":"NexImmune .."}]

    Find Clinical Drug Pipeline Developments & Deals by NexImmune

    Menu

    NexImmune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Discovery

                            Sponsor : JDRF

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes

                            Details : The partnership aims to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb,a murine surrogate of teplizumab, to tolerize, deplete or modulate diabetes antigen-specific ...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 24, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Discovery

                            Sponsor : JDRF

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEXI-004

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company’s AIM Platform...

                            Details : NEXI-004 is a patient derived stem cell developed using adoptive cell therapy modality technology which is being developed for EBV associated diseases. It is currently in preclinical stage of development.

                            Brand Name : NEXI-004

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 18, 2023

                            Lead Product(s) : NEXI-004

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Immunology

                            Study Phase : Discovery

                            Sponsor : National Institute of Neurological Disorders and Stroke

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and S...

                            Details : The goal of this collaboration is to develop adoptive cell therapies that may benefit patients afflicted with immunological disorders related to Epstein-Barr virus (EBV) and Human T-cell Leukemia Virus, t...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 06, 2022

                            Lead Product(s) : T-Cell Therapy

                            Therapeutic Area : Immunology

                            Highest Development Status : Discovery

                            Sponsor : National Institute of Neurological Disorders and Stroke

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLA IgG4 Fusion Proteins,T-cell Co-stimulatory Monoclonal Antibodies

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Ca...

                            Details : The agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that h...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 08, 2022

                            Lead Product(s) : HLA IgG4 Fusion Proteins,T-cell Co-stimulatory Monoclonal Antibodies

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : KBI Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEXI-003

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Canc...

                            Details : IND clearance enables commencement of a clinical trial to evaluate NEXI-003, an autologous antigen-specific T cell product (CD3+/CD4-), in patients with relapsed or refractory human papillomavirus (HPV)-r...

                            Brand Name : NEXI-003

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            July 14, 2022

                            Lead Product(s) : NEXI-003

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T1D Antigen-specific Nanoparticle,Teplizumab

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : JDRF

                            Deal Size : $0.6 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

                            Details : The JDRF award will fund efforts to investigate the use of NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab. The investigation will test this hypothesis in a preclinica...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 10, 2022

                            Lead Product(s) : T1D Antigen-specific Nanoparticle,Teplizumab

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : JDRF

                            Deal Size : $0.6 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adoptive Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Columbia University Irving Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Cen...

                            Details : The research will focus on the use of NexImmune’s adoptive cell therapy, AIM ACT, in Columbia’s patient-derived organoid (PDO) models of HPV-associated cancers, including head and neck squamous cell c...

                            Brand Name : AIM ACT

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            April 26, 2022

                            Lead Product(s) : Adoptive Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Columbia University Irving Medical Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neoantigen-specific CD8+ T Cells

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : The Laura and Isaac Perlmutter Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center

                            Details : The collaboration is centered around NexImmune’s artificial antigen presenting cells' (aAPCs) ability to expand neoantigen-specific CD8+ T cells in apheresis material provided by melanoma patients.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 14, 2022

                            Lead Product(s) : Neoantigen-specific CD8+ T Cells

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : The Laura and Isaac Perlmutter Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEXI-001

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation ...

                            Details : Preliminary data from its first-in-human study of NEXI-001, a multi-antigen specific CD8+ T cell product, in acute myeloid leukemia (AML) patients with relapsed disease has been selected for an oral prese...

                            Brand Name : NEXI-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 04, 2020

                            Lead Product(s) : NEXI-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            NexImmune

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NEXI-002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NexImmune First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myelom...

                            Details : NEXI-002 is a patient-derived cellular product that contains populations of naturally-occurring CD8+ T cells directed against several multiple myeloma (MM)-specific antigen targets. It is the second clini...

                            Brand Name : NEXI-002

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 06, 2020

                            Lead Product(s) : NEXI-002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth